Halter Ferguson Financial Inc. Acquires 155,996 Shares of Candel Therapeutics, Inc. $CADL

Halter Ferguson Financial Inc. grew its holdings in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) by 20.9% during the 1st quarter, HoldingsChannel reports. The fund owned 904,051 shares of the company’s stock after acquiring an additional 155,996 shares during the quarter. Candel Therapeutics makes up 1.0% of Halter Ferguson Financial Inc.’s investment portfolio, making the stock its 13th biggest position. Halter Ferguson Financial Inc.’s holdings in Candel Therapeutics were worth $4,430,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in CADL. Vanguard Group Inc. boosted its stake in shares of Candel Therapeutics by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock valued at $10,236,000 after purchasing an additional 219,563 shares in the last quarter. Geode Capital Management LLC raised its position in Candel Therapeutics by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 977,512 shares of the company’s stock worth $5,524,000 after purchasing an additional 49,315 shares during the period. State Street Corp lifted its stake in Candel Therapeutics by 15.0% in the fourth quarter. State Street Corp now owns 792,218 shares of the company’s stock worth $4,476,000 after purchasing an additional 103,452 shares during the last quarter. Millennium Management LLC bought a new stake in Candel Therapeutics in the third quarter worth $697,000. Finally, Wells Fargo & Company MN lifted its stake in Candel Therapeutics by 180.9% in the fourth quarter. Wells Fargo & Company MN now owns 73,899 shares of the company’s stock worth $418,000 after purchasing an additional 47,588 shares during the last quarter. 13.93% of the stock is owned by hedge funds and other institutional investors.

Candel Therapeutics Trading Up 2.0%

NASDAQ:CADL opened at $10.03 on Tuesday. The firm has a market capitalization of $734.90 million, a P/E ratio of -10.23 and a beta of -0.52. The company has a quick ratio of 28.05, a current ratio of 28.05 and a debt-to-equity ratio of 0.34. The company has a fifty day moving average of $8.41 and a 200 day moving average of $6.54. Candel Therapeutics, Inc. has a 52 week low of $4.35 and a 52 week high of $11.36.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.16. On average, research analysts predict that Candel Therapeutics, Inc. will post -0.97 earnings per share for the current year.

Insider Transactions at Candel Therapeutics

In related news, CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $10.02, for a total value of $70,140.00. Following the sale, the chief technology officer directly owned 83,865 shares of the company’s stock, valued at $840,327.30. This trade represents a 7.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Francesca Barone sold 23,447 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $10.06, for a total value of $235,876.82. Following the transaction, the insider owned 77,362 shares in the company, valued at approximately $778,261.72. This represents a 23.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 14.30% of the company’s stock.

Analysts Set New Price Targets

CADL has been the topic of a number of recent research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Candel Therapeutics in a research note on Friday, March 13th. Cantor Fitzgerald initiated coverage on Candel Therapeutics in a research note on Monday, April 20th. They issued an “overweight” rating for the company. Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Citigroup reduced their price target on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, March 13th. Finally, Wall Street Zen raised Candel Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, June 1st. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Candel Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $18.00.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.